 NEWTOWN, Pa., Oct. 26, 2020 GLOBE NEWSWIRE -- Helius Medical Technologies, Inc. Nasdaq:HSDT TSX:HSM Helius or the Company, a neurotech company focused on neurological wellness, announced today that it has closed its previously announced private placement for total gross proceeds of approximately 3.4 million. The private placement consisted of an aggregate of 6,567,868 shares of the Companys Class A Common Stock, or common stock, and warrants to purchase an aggregate of 3,283,936 shares of common stock, at a purchase price of 0.52 per unit, consisting of one share of common stock and a warrant to purchase 0.50 shares of common stock, which aggregate share amounts reflect corrections to the previously announced numbers. The warrants have an exercise price of 0.452 per share of common stock and are exercisable for a period of three years from the date of issuance. Helius intends to use the net proceeds from the offering for funding operations, working capital and general corporate purposes. 